Semaglutide is the compound that made GLP-1 drugs a household topic, and it's also one of the most misunderstood in terms of what "FDA-approved" actually covers. That distinction matters more here than for almost anything else on this site.
What semaglutide is
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a synthetic analog of a natural gut hormone that regulates insulin secretion, appetite, and gastric emptying. It's marketed as a prescription pharmaceutical under the brand names Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management).
What's actually been studied
- The STEP trial program. A large series of randomized, placebo-controlled trials (STEP 1 through STEP UP) tested semaglutide for chronic weight management in adults with obesity or overweight, in human subjects, over periods extending to two years. These trials reported substantial average weight loss compared with placebo, alongside improvements in several cardiometabolic markers (STEP 5, two-year results, PMC; systematic review and meta-analysis including STEP 5, Diabetes, Obesity and Metabolism, 2024).
- Weight regain after stopping. A follow-up analysis of the STEP 1 trial extension found that participants regained a substantial portion of lost weight after semaglutide was discontinued, alongside reversal of some cardiometabolic improvements (STEP 1 extension, PMC).
- Regulatory record. The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in April 2021, based on the STEP trial program, and later approved a higher-dose formulation as well (StatPearls, NCBI Bookshelf).
Where the evidence is thin
The human trial evidence for semaglutide's approved indications is genuinely strong, this isn't a compound running on animal data or a single small study. The gap that matters for this audience is different: the FDA approval covers a specific, pharmaceutical-grade, prescription product, dispensed and monitored by a physician, not the unbranded "research peptide" vials sold by research chemical vendors. Those vials are not the approved drug, haven't been through the same manufacturing and quality oversight, and using one outside clinical supervision isn't what any of the cited trials actually tested.
The regulatory picture
Semaglutide is FDA-approved as a prescription drug (Ozempic, Rybelsus, Wegovy) for specific, defined indications, under physician supervision. It is not approved for self-directed, unsupervised use, and the research-chemical version sold for laboratory research is a legally and practically different product from what was studied in the trials above. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
This is the rare case where I'm not skeptical of the underlying science, the STEP program is about as solid as clinical trial evidence gets in this space. What I am skeptical of is the framing that treats "semaglutide is FDA-approved" as if it settles the question of using a research-chem vial on your own. It doesn't. The approval, the monitoring, and the trial data all apply to a specific prescription product, not to what's sitting in a vial from a research supplier.
Sources
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, PMC
- Efficacy and safety of semaglutide 2.4 mg for weight loss: an updated systematic review and meta-analysis including the STEP 5 trial, Diabetes, Obesity and Metabolism, 2024
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, PMC
- Semaglutide, StatPearls, NCBI Bookshelf
Sourcing for research
If you're sourcing semaglutide for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.